VistaGen Free Cash Flow from 2010 to 2024

VTGN Stock  USD 3.93  0.07  1.81%   
VistaGen Therapeutics Free Cash Flow yearly trend continues to be very stable with very little volatility. Free Cash Flow is likely to grow to about -42.7 M this year. Free Cash Flow is the amount of cash VistaGen Therapeutics generates after accounting for cash outflows to support operations and maintain its capital assets. View All Fundamentals
 
Free Cash Flow  
First Reported
2007-03-31
Previous Quarter
-6.2 M
Current Value
-4.6 M
Quarterly Volatility
M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check VistaGen Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VistaGen main balance sheet or income statement drivers, such as Interest Expense of 25.1 K, Selling General Administrative of 12.5 M or Other Operating Expenses of 71.3 M, as well as many exotic indicators such as Dividend Yield of 0.0, Average Payables of 0.0 or ROIC of 20.05. VistaGen financial statements analysis is a perfect complement when working with VistaGen Therapeutics Valuation or Volatility modules.
  
This module can also supplement VistaGen Therapeutics' financial leverage analysis and stock options assessment as well as various VistaGen Therapeutics Technical models . Check out the analysis of VistaGen Therapeutics Correlation against competitors.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.

Latest VistaGen Therapeutics' Free Cash Flow Growth Pattern

Below is the plot of the Free Cash Flow of VistaGen Therapeutics over the last few years. It is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets. VistaGen Therapeutics' Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in VistaGen Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow10 Years Trend
Slightly volatile
   Free Cash Flow   
       Timeline  

VistaGen Free Cash Flow Regression Statistics

Arithmetic Mean(17,287,698)
Coefficient Of Variation(106.37)
Mean Deviation15,180,702
Median(9,059,900)
Standard Deviation18,389,003
Sample Variance338.2T
Range49.9M
R-Value(0.88)
Mean Square Error84.2T
R-Squared0.77
Significance0.000018
Slope(3,605,391)
Total Sum of Squares4734.2T

VistaGen Free Cash Flow History

2024-42.7 M
2023-44.9 M
2022-49.9 M
2021-45.5 M
2020-12.3 M
2019-15.8 M
2018-14.7 M

Other Fundumenentals of VistaGen Therapeutics

VistaGen Therapeutics Free Cash Flow component correlations

About VistaGen Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include VistaGen Therapeutics income statement, its balance sheet, and the statement of cash flows. VistaGen Therapeutics investors use historical funamental indicators, such as VistaGen Therapeutics's Free Cash Flow, to determine how well the company is positioned to perform in the future. Although VistaGen Therapeutics investors may use each financial statement separately, they are all related. The changes in VistaGen Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on VistaGen Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on VistaGen Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in VistaGen Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Free Cash Flow-44.9 M-42.7 M
Free Cash Flow Yield(0.0002)(0.0003)
Free Cash Flow Per Share(0.35)(0.37)
EV To Free Cash Flow-4.2 K-4.4 K
Price To Free Cash Flows Ratio-4.2 K-4.4 K
Free Cash Flow Operating Cash Flow Ratio 1.09  1.12 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:
Check out the analysis of VistaGen Therapeutics Correlation against competitors.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
Note that the VistaGen Therapeutics information on this page should be used as a complementary analysis to other VistaGen Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for VistaGen Stock analysis

When running VistaGen Therapeutics' price analysis, check to measure VistaGen Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VistaGen Therapeutics is operating at the current time. Most of VistaGen Therapeutics' value examination focuses on studying past and present price action to predict the probability of VistaGen Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VistaGen Therapeutics' price. Additionally, you may evaluate how the addition of VistaGen Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is VistaGen Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.96)
Revenue Per Share
0.077
Quarterly Revenue Growth
1.291
Return On Assets
(0.26)
Return On Equity
(0.45)
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.